Marc Goodman
Stock Analyst at Leerink Partners
(2.93)
# 1,678
Out of 5,015 analysts
93
Total ratings
56.76%
Success rate
28.23%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $15.44 | +120.21% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $15.80 | +216.46% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $14.26 | -29.87% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $121.71 | +23.24% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $2.04 | -50.98% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $38.79 | -17.50% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $79.27 | -68.46% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $15.37 | +225.31% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $6.14 | +225.73% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $136.63 | -15.83% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $146.57 | +111.50% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $14.00 | -14.29% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $39.64 | +16.04% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $20.06 | +4.69% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $135.43 | +55.06% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.55 | +181.69% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $31.21 | -13.49% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.39 | +178.29% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $549.28 | -50.84% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $230.50 | -58.35% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $43.96 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $85.99 | -22.08% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $21.25 | +361.18% | 7 | Oct 5, 2017 |
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $15.44
Upside: +120.21%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $15.80
Upside: +216.46%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $14.26
Upside: -29.87%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $121.71
Upside: +23.24%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $2.04
Upside: -50.98%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $38.79
Upside: -17.50%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $79.27
Upside: -68.46%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $15.37
Upside: +225.31%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.14
Upside: +225.73%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $136.63
Upside: -15.83%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $146.57
Upside: +111.50%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $14.00
Upside: -14.29%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $39.64
Upside: +16.04%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $20.06
Upside: +4.69%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $135.43
Upside: +55.06%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.55
Upside: +181.69%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $31.21
Upside: -13.49%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.39
Upside: +178.29%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $549.28
Upside: -50.84%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $230.50
Upside: -58.35%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $43.96
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $85.99
Upside: -22.08%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $21.25
Upside: +361.18%